Immune Pharmaceuticals Inc. (IMNP) Short Interest Update
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 2,972,192 shares, an increase of 47.6% from the August 31st total of 2,013,511 shares. Currently, 4.4% of the company’s stock are sold short. Based on an average daily trading volume, of 3,758,535 shares, the short-interest ratio is currently 0.8 days.
Separately, FBR & Co reiterated a “buy” rating on shares of Immune Pharmaceuticals in a research note on Wednesday, June 22nd.
Shares of Immune Pharmaceuticals (NASDAQ:IMNP) opened at 0.2675 on Friday. The stock’s 50 day moving average is $0.32 and its 200 day moving average is $0.38. Immune Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $1.54. The stock’s market cap is $21.18 million.
Immune Pharmaceuticals (NASDAQ:IMNP) last announced its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). On average, equities analysts forecast that Immune Pharmaceuticals will post ($0.56) EPS for the current year.
In other news, CEO Daniel Gedeon Teper acquired 937,500 shares of the firm’s stock in a transaction on Thursday, August 4th. The stock was purchased at an average price of $0.38 per share, for a total transaction of $356,250.00. Following the purchase, the chief executive officer now owns 5,748,405 shares in the company, valued at approximately $2,184,393.90. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel Kazado acquired 666,667 shares of the firm’s stock in a transaction on Thursday, August 4th. The stock was purchased at an average price of $0.45 per share, with a total value of $300,000.15. Following the purchase, the director now owns 907,290 shares in the company, valued at approximately $408,280.50. The disclosure for this purchase can be found here. 17.83% of the stock is currently owned by company insiders.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.